Bristol Myers Squibb

News

BMS signs $475m cancer immunotherapy deal with Dragonfly

Bristol-Myers Squibb has signed an agreement worth $475 million to develop a new form of cancer immunotherapy drug with US biotech Dragonfly Therapeutics.

News

Will Gottlieb follow up on Trump's promise of a bonfire of regulations?

FDA to decide on TG Therapeutics' lymphoma drug early next y...

The FDA has accepted TG Therapeutics’ filing for its lymphoma drug umbralisib, which if approved could compete against a combination therapy from Bristol-Myers Squibb and Roche.

News

BMS’ Opdivo aces trial in asbestos-linked lung cancer

Bristol-Myers Squibb’s Opdivo has improved survival in a trial involving patients with mesothelioma, a form of lung cancer, getting one up over rival checkpoint inhibitor Keytr

News

Roche’s Tecentriq claims melanoma OK, but don’t expect a sal...

Roche’s checkpoint inhibitor Tecentriq has been cleared for another new use in the US – in melanoma – but could struggle to displace rival drugs from Bristol-Myers Squibb and M

News

BMS 'bet' with Celgene shareholders in balance after CAR-T r...

Bristol-Myers Squibb and bluebird bio have refiled their CAR-T therapy for multiple myeloma, leaving the outcome of a three drug “bet” with former Celgene shareholders dependent on a fast r

Views & Analysis

ASCO 2020: Scientific advances & what’s impacting doctors an...

Despite going virtual due to the COVID-19 pandemic, Jennifer Harris, an immuno-oncology expert from Syneos Health told pharmaphorum’s Richard Staines that the 2020 American Society of Clini

BMS signs $475m cancer immunotherapy deal with Dragonfly

FDA to decide on TG Therapeutics' lymphoma drug early next y...

BMS’ Opdivo aces trial in asbestos-linked lung cancer

Roche’s Tecentriq claims melanoma OK, but don’t expect a sal...

BMS 'bet' with Celgene shareholders in balance after CAR-T r...

ASCO 2020: Scientific advances & what’s impacting doctors an...

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

Bristol Myers Squibb

Editor's Picks